Condition: Advanced / Metastatic Solid Tumor · Sponsor: Stingray Therapeutics
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors.
This description comes directly from the study's public registry record.
Sunil Sharma · 602-343-8402 · Sunil Sharma <ssharma@honorhealth.com>
Jonathan Northrup · 317-517-9500 · jon@stingraytx.com
Always discuss trial participation with your own doctor first.
| Scientia Clinical Research Ltd | Randwick, New South Wales, Australia | Recruiting |
| Monash Health | Clayton, Victoria, Australia | Recruiting |
| Peninsula & South Eastern Haematology & Oncology Group | Frankston, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06063681